Literature DB >> 9121769

Human p57(KIP2) defines a new imprinted domain on chromosome 11p but is not a tumour suppressor gene in Wilms tumour.

T Taniguchi1, K Okamoto, A E Reeve.   

Abstract

Mouse p57(Kip2) arrests cells in G1 by functioning as a strong inhibitor of several G1 cyclin/Cdk complexes (Lee et al., 1995; Matsuoka et al., 1995; Sherr and Roberts, 1995). Human p57(KIP2) has been suggested to be a tumour suppressor gene because of its location at 11p15.5 which frequently undergoes maternal allele LOH in several types of cancer (Matsuoka et al., 1995; Sherr and Roberts, 1995; Hatada and Mukai, 1995). This suggestion was supported by the discovery that mouse p57(Kip2) is imprinted with expression from only the maternally inherited allele (Hatada and Mukai, 1995). Interestingly, p57(KIP2) is several hundred kilobases from the imprinted H19 and IGF2 genes which are involved in growth regulation (Hoovers et al., 1995). Here we show that human p57(KIP2) is imprinted with expression from the maternal allele. However, unlike the mouse, the imprinting is incomplete with significant expression from the paternal allele depending on the tissue examined. We have also shown that the imprinting of p57(KIP2) occurs independently of the H19/IGF2 domain and thus there must be at least two imprinted domains in 11p15.5. Finally, by examining Wilms tumours we have shown that following maternal 11p LOH, p57(KIP2) was expressed from the paternal allele. Therefore, p57(KIP2) cannot function as an imprinted tumour suppressor gene, at least in Wilms tumour.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9121769     DOI: 10.1038/sj.onc.1200934

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  Is p57KIP2 mutation a common mechanism for Beckwith-Wiedemann syndrome or somatic overgrowth?

Authors:  K Okamoto; I M Morison; A E Reeve; N Tommerup; H R Wiedemann; U Friedrich
Journal:  J Med Genet       Date:  1998-01       Impact factor: 6.318

Review 2.  Cip/Kip cell-cycle inhibitors: a neuro-oncological perspective.

Authors:  T G Mainprize; M D Taylor; J T Rutka; P B Dirks
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

3.  Expression of p57(KIP2) potently blocks the growth of human astrocytomas and induces cell senescence.

Authors:  A Tsugu; K Sakai; P B Dirks; S Jung; R Weksberg; Y L Fei; S Mondal; S Ivanchuk; C Ackerley; P A Hamel; J T Rutka
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

4.  Methylation alterations of the MyoD1 upstream region are predictive of subclassification of human rhabdomyosarcomas.

Authors:  B Chen; P Dias; J J Jenkins; V H Savell; D M Parham
Journal:  Am J Pathol       Date:  1998-04       Impact factor: 4.307

5.  Genetic and epigenetic alterations on the short arm of chromosome 11 are involved in a majority of sporadic Wilms' tumours.

Authors:  Y Satoh; H Nakadate; T Nakagawachi; K Higashimoto; K Joh; Z Masaki; J Uozumi; Y Kaneko; T Mukai; H Soejima
Journal:  Br J Cancer       Date:  2006-08-08       Impact factor: 7.640

6.  p53 gene mutation and loss of heterozygosity of chromosome 11 in methylcholanthrene-induced mouse sarcomas.

Authors:  K Shimokado; H Watanabe; M Sumii; K Miyagawa; K Kamiya; K Dohi; O Niwa
Journal:  Jpn J Cancer Res       Date:  1998-03

7.  Fetal growth restriction in a genetic model of sporadic Beckwith-Wiedemann syndrome.

Authors:  Simon J Tunster; Mathew Van de Pette; Hugo D J Creeth; Louis Lefebvre; Rosalind M John
Journal:  Dis Model Mech       Date:  2018-11-16       Impact factor: 5.758

8.  Evolution of the CDKN1C-KCNQ1 imprinted domain.

Authors:  Eleanor I Ager; Andrew J Pask; Helen M Gehring; Geoff Shaw; Marilyn B Renfree
Journal:  BMC Evol Biol       Date:  2008-05-29       Impact factor: 3.260

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.